RhumbLine Advisers’s Acer Therapeutics Inc ACER Stock Holding History

RhumbLine Advisers’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-347	Closed	-$286	–	4305
2023 Q3	$286	Hold	347	–	–	﹤0.01%	4258
2023 Q2	$320	Buy	+347	New	+$308	﹤0.01%	4336

Other funds holding ACER

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

RhumbLine Advisers's ACER Position: Q4 2023 in Review

RhumbLine Advisers sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 347 shares — an estimated $286 sold.

RhumbLine Advisers first reported a position in ACER in Q2 2023 and held it in 2 quarters. The position peaked at $320 in Q2 2023. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.

RhumbLine Advisers reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
RhumbLine Advisers sold 347 Acer Therapeutics Inc shares in Q4 2023, an estimated $286.
RhumbLine Advisers first reported a position in Acer Therapeutics Inc in Q2 2023 and held it in 2 quarters.
RhumbLine Advisers's Acer Therapeutics Inc position peaked at $320 in Q2 2023.
2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.